Latest news with #VoltPFASystem
Yahoo
05-05-2025
- Business
- Yahoo
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib). The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications (just 4.7 applications per vein on average) than on-market competitive PFA systems. PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms. Abbott designed its Volt CE Mark Study to assess the impact of the Volt PFA System in two different patient groups – people battling paroxysmal atrial fibrillation (PAF) - episodes that come and go - as well as persistent AFib (PersAF) - episodes that last longer than seven days. The 12-month data from the Volt CE Mark Study were presented at the 2025 Heart Rhythm Society (HRS) annual meeting held in San Diego (April 24-27, 2025) and simultaneously published in Heart Rhythm, the official journal of the Heart Rhythm Society. Sustained Performance of the Volt PFA SystemData from the Volt CE Mark Study showed that after 12 months, Abbott's Volt PFA System delivered: Outstanding long-term performance. The Volt PFA System demonstrated sustained performance in both safety and effectiveness out to 12 months for patients with PAF and PersAF. Freedom from arrhythmia. 83.5% of PAF patients and 58.1% of PersAF patients remained free from atrial arrhythmia after 12 months – one of the lowest rates of reoccurrence in PAF patients in a long-term PFA study to date. Quality of life (QoL) benefits. After 12 months, the Volt CE Mark Study showed a significant QoL benefit for patients, with QoL assessment scores improving from 64.1 to 88.1. Excellent safety profile. After 12 months, just 2.7% of Volt patients had experienced a primary safety endpoint event with zero patients suffering from hemolysis (destruction of red blood cells), coronary artery spasm, pulmonary vein stenosis, acute kidney injury, or phrenic nerve injury – all potential challenges of PFA therapy. "The long-term 12-month results from the Volt CE Mark Study paint a picture of a PFA system that performs exceptionally well in two different groups of patients – each with unique therapy needs and clinical approaches," said Prof. Gian-Battista Chierchia, director of the Atrial Fibrillation Program at the Heart Rhythm Management Institute at the University of Brussels in Belgium. "These long-term data provide us a strong picture of how the Volt PFA System will perform in clinical settings as we leverage PFA therapy for our patients." To date, clinical experience following CE Mark has further confirmed that the Volt PFA System can support treating patients battling either PAF or PersAF, allowing the system to help as many patients as possible. The Volt PFA System also provides a single-catheter PFA approach, improves workflow and provides procedural flexibility by allowing for light sedation or general anesthesia. A new sub-analysis from the VOLT-AF IDE Study presented at HRS 2025 showed no significant difference in safety or acute effectiveness outcomes in cases performed under conscious or deep sedation when compared to procedures performed with general anesthesia. "Our goal from the beginning with the Volt PFA System was to design a PFA system that would provide outstanding results in patients battling a range of atrial arrhythmias, and the latest data from the Volt CE Mark Study is confirmation that the system will truly impact patient care in a positive way," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. About the Volt CE Mark StudyAbbott's Volt CE Mark Study is a prospective, single-arm, non-randomized, multicenter study designed to demonstrate the safety and effectiveness of the Volt PFA System for the treatment of symptomatic, recurrent, drug-refractory PAF and PersAF. The study enrolled 150 patients at 11 sites across Europe and included a feasibility sub-study in which additional imaging assessments were collected to confirm the acute safety of the Volt PFA System. About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. View original content: SOURCE Abbott
Yahoo
28-04-2025
- Business
- Yahoo
Abbott reports new data from study of PFA system for atrial fibrillation
Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated with pulsed field ablation (PFA) therapy using the Volt PFA System for atrial fibrillation (AFib) showed efficacy and safety up to 12 months. This study was designed to evaluate the system's impact on two distinct subject groups: those with paroxysmal atrial fibrillation (PAF), in which episodes come and go, and those with persistent AFib (PersAF), where episodes last longer than seven days. A total of 150 subjects were enrolled in this single-arm, multicentre study across 11 European sites, and it also included a feasibility sub-study with additional imaging evaluations to confirm the system's acute safety. According to the study data, after one year, the system achieved results, with 83.5% of PAF subjects and 58.1% of PersAF subjects remaining atrial arrhythmia-free. Additionally, the quality of life (QoL) assessment scores improved from 64.1 to 88.1 over the same period. The safety profile of the system was also found to be notable, with 2.7% of subjects experiencing a primary safety endpoint event, and no cases of haemolysis, acute kidney injury, pulmonary vein stenosis, coronary artery spasm, or phrenic nerve injury reported. The system offers a single-catheter PFA approach, enhances workflow and procedural flexibility, enabling either light sedation or general anaesthesia. A sub-analysis from the study found no significant difference in safety or acute effectiveness results between procedures performed under conscious or deep sedation and those with general anaesthesia. Abbott electrophysiology business chief medical officer Christopher Piorkowski said: "Our goal from the beginning with the Volt PFA system was to design a PFA system that would provide outstanding results in patients battling a range of atrial arrhythmias, and the latest data from the Volt CE Mark Study is confirmation that the system will truly impact patient care in a positive way.' Earlier this month, the company launched a next-generation delivery system to simplify the electrode implantation process for its Proclaim DRG neurostimulation system. "Abbott reports new data from study of PFA system for atrial fibrillation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Insider
28-04-2025
- Health
- Business Insider
Abbott announces new data from its Volt CE Mark Study
Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation, PFA, therapy with the Volt PFA System for the treatment of atrial fibrillation. The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications than on-market competitive PFA systems. PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms. Abbott designed its Volt CE Mark Study to assess the impact of the Volt PFA System in two different patient groups – people battling paroxysmal atrial fibrillation – episodes that come and go – as well as persistent AFib – episodes that last longer than seven days. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Yahoo
29-03-2025
- Business
- Yahoo
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday
Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a share price gain on the day that approached 4%. This was more than good enough to top the S&P 500 index, which closed Thursday 0.3% lower. That morning, Abbott announced that it earned a CE mark in Europe for its Volt PFA System, a product used to treat people with atrial fibrillation (a common heart disorder). PFA stands for pulsed field ablation, which basically means that the system utilizes high-energy electrical pulses to target and treat tissues in the organ that might be contributing to problems. The CE mark is an affirmation by a product's manufacturer that it conforms with a range of standards covering aspects such as health and safety. It is required for goods sold throughout the European Economic Area, which covers most of that continent. In its press release touting the development, Abbott wrote that roughly 8 million people in Europe over the age of 65 are coping with atrial fibrillation, and that figure is anticipated to double within three decades. Abbott clearly believes that Volt PFA is a very competitive product, and investors seem to agree. In the press release, the healthcare company quoted the chief medical officer of its electrophysiology unit Christopher Piorkowski as saying that while PFA is a comparatively new therapy, "We've incorporated lessons learned from first-generation devices and designed the Volt system to simplify PFA procedures while making them more efficient." Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $295,009!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $42,000!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $523,463!* Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 24, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy. Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday was originally published by The Motley Fool
Yahoo
28-03-2025
- Business
- Yahoo
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday
Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a share price gain on the day that approached 4%. This was more than good enough to top the S&P 500 index, which closed Thursday 0.3% lower. That morning, Abbott announced that it earned a CE mark in Europe for its Volt PFA System, a product used to treat people with atrial fibrillation (a common heart disorder). PFA stands for pulsed field ablation, which basically means that the system utilizes high-energy electrical pulses to target and treat tissues in the organ that might be contributing to problems. The CE mark is an affirmation by a product's manufacturer that it conforms with a range of standards covering aspects such as health and safety. It is required for goods sold throughout the European Economic Area, which covers most of that continent. In its press release touting the development, Abbott wrote that roughly 8 million people in Europe over the age of 65 are coping with atrial fibrillation, and that figure is anticipated to double within three decades. Abbott clearly believes that Volt PFA is a very competitive product, and investors seem to agree. In the press release, the healthcare company quoted the chief medical officer of its electrophysiology unit Christopher Piorkowski as saying that while PFA is a comparatively new therapy, "We've incorporated lessons learned from first-generation devices and designed the Volt system to simplify PFA procedures while making them more efficient." Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $295,009!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $42,000!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $523,463!* Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 24, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy. Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday was originally published by The Motley Fool Sign in to access your portfolio
